Literature DB >> 16181139

Definition of an uptake pharmacophore of the serotonin transporter through 3D-QSAR analysis.

J Pratuangdejkul1, B Schneider, P Jaudon, V Rosilio, E Baudoin, S Loric, M Conti, J-M Launay, P Manivet.   

Abstract

The serotonergic system plays a critical role in a wide variety of physiological and behavioral processes. Dysregulation of the tightly controlled extracellular concentration of serotonin (5-hydroxytryptamine, 5-HT) appears to be at the origin of a host of metabolic and psychiatric disorders. Since the plasma membrane 5-HT transporter (SERT) is the major protagonist in regulating extracellular 5-HT concentration, SERT is the target of most drugs interacting with the serotonergic system. Unfortunately, some of the drugs towards SERT (e.g. amphetamine derivatives) interfere with cell homeostasis leading to cell toxicity. Developing new SERT ligands devoid of any side-effect represents a major priority in the treatment of 5-HT-associated pathologies. Here, we report structure-activity relationships (SAR) and three-dimensional QSAR (3D-QSAR) studies of a library of 121 compounds including 5-HT analogs, harmanes, benzothiazoles, indanones, amphetamine derivatives and substrate-type 5-HT releasers, with the goal of identifying the structural determinants crucial for SERT uptake. In the absence of data about the bioactive form of 5-HT, conformational analysis of 5-HT was performed using quantum chemistry calculations. This led to three 5-HT stable conformers with anti, -gauche and +gauche side-chain conformation. These conformers, used as templates for superimposition with all the library compounds, enabled the design of a reliable 6-points pharmacophore representative of SERT uptake activity. Molecular dynamics (MD) simulations performed with compounds that are efficiently, moderately, poorly or not transported by SERT allowed to assess the validity of our pharmacophore. Altogether, our data provide for the first time a reliable pharmacophore of SERT uptake activity, which may help to the design of new drugs targeting SERT.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16181139     DOI: 10.2174/0929867054864813

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  4 in total

1.  Discovery of novel selective serotonin reuptake inhibitors through development of a protein-based pharmacophore.

Authors:  Sankar Manepalli; Laura M Geffert; Christopher K Surratt; Jeffry D Madura
Journal:  J Chem Inf Model       Date:  2011-09-02       Impact factor: 4.956

Review 2.  Monoamine transporter structure, function, dynamics, and drug discovery: a computational perspective.

Authors:  Sankar Manepalli; Christopher K Surratt; Jeffry D Madura; Tammy L Nolan
Journal:  AAPS J       Date:  2012-08-24       Impact factor: 4.009

3.  Substrate binding and formation of an occluded state in the leucine transporter.

Authors:  Leyla Celik; Birgit Schiøtt; Emad Tajkhorshid
Journal:  Biophys J       Date:  2007-11-16       Impact factor: 4.033

4.  Plasma and platelet serotonin levels in patients with liver cirrhosis.

Authors:  Dorde M Culafic; Dusko S Mirkovic; Miodrag D Vukcevic; Jelena S Rudic
Journal:  World J Gastroenterol       Date:  2007-11-21       Impact factor: 5.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.